Tetragenetics, Inc.

17 articles about Tetragenetics, Inc.

• TetraGenetics Announces Discovery of Functional Antibodies Against Nav1.8 at the Antibody Engineering & Therapeutics Virtual Conference

  12/14/2020

  TetraGenetics , a biopharmaceutical company developing novel antibody therapeutics for ion-channel mediated disorders, announced today that they will be presenting news of the discovery of functional antibodies against Nav1.8 at the Antibody Engineering & Therapeutics Virtual Conference taking place Dec 14 th – 16 th . The success of TetraGenetics is based on its strategy for identifying function-modulating antibodies

• Abveris and TetraGenetics Announce Antibody Discovery Collaboration

  6/4/2019

  Abveris, Inc., a leader in contract research antibody discovery, announced that it has entered into a multi-target agreement with TetraGenetics, Inc.

• TetraGenetics Appoints Alison Taunton-Rigby, Ellen Baron and Daniel Grau to its Board of Directors

  5/2/2019

  Biopharma and Investment Executives with Deep Industry Experience to Support Continued Growth of TetraGenetics Ion Channel Pipeline and Platform

• Imbrium Therapeutics and TetraGenetics Announce Strategic Research Collaboration and License Option to Develop Novel Biologic Therapeutics for Pain

  2/26/2019

  TetraGenetics to receive up to $25 million in upfront license and FTE payments; is eligible to receive total contingent payments up to $248 million plus royalties

• TetraGenetics Expands Collaboration With Top Tier Biotech Partner

  2/13/2018

  Tetragenetics, Inc. announced today a significant expansion of an existing strategic R&D collaboration with an industry leading biotech partner.

• TetraGenetics Partners With LifeArc to Humanize New Drugs and Perform IND-Enabling Studies

  12/12/2017

  Under the agreement LifeArc will humanize up to five new drug leads discovered by TetraGenetics and may support pre-IND (Investigational New Drug) studies for selected programs.

• TetraGenetics and ModiQuest Collaborating for the Discovery of Therapeutic Antibodies Against KCa3.1

  12/6/2017

  The alliance is focused on the discovery of novel monoclonal antibodies against KCa3.1, a well-validated target for fibrosis, vasculoproliferative disorders and immunomodulation to treat autoimmune and inflammatory disorders.

• Tetragenetics, Inc. Announces Another Strategic Partnership With A Top Ten Pharmaceutical Company

  8/29/2016

• Tetragenetics, Inc. And Theranyx Partner For Discovery And Development Of Therapeutic Monoclonal Antibodies

  5/25/2016

• Tetragenetics, Inc. Awarded $1.5M Research And Development Grant By NIH

  1/11/2016

• Tetragenetics, Inc. Launches Partnership Program For Discovery And Development Of Therapeutic Monoclonal Antibodies

  12/17/2015

• Tetragenetics, Inc. Collaborates With MedImmune On Multi-Target Ion Channel Drug Discovery Program

  1/7/2015

• Tetragenetics, Inc. Announces New Collaboration in SionX™ Technology

  4/3/2013

• Tetragenetics, Inc. Announces Collaboration With Amgen

  4/2/2013

• Tetragenetics, Inc. Receives Phase II Grand Challenges Explorations Funding

  4/1/2013

• Tetragenetics, Inc.’ G-SOME™-Formulated Influenza Vaccine Provides Strong Protection Against H5N1 in Preclinical Efficacy Study

  1/5/2012

• Tetragenetics, Inc. Announces New CEO and Expands Board of Directors

  6/13/2011